Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 5/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 8/20 | 0.36 |
| ▸ | HTR2B | P41595 | 7/20 | 0.36 |
| ▸ | HTR2A | P28223 | 5/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4398458 | 1.00 | SLC5A2 (0.40) | SLC5A2SLC6A2SLC6A4SLC6A3CYP2C19 | |
| SCHEMBL10590087 | 0.90 | SLC5A2 (0.45) | SLC5A2CYP2C19CYP3A4CYP2D6MAPT | |
| SCHEMBL2384795 | 0.90 | SLC5A2 (0.45) | SLC5A2CYP2C19CYP3A4CYP2D6MAPT | |
| SCHEMBL22577266 | 0.90 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3CYP2C19HTR2C | |
| SCHEMBL13590060 | 0.90 | SLC5A2 (0.45) | SLC5A2CYP2C19CYP3A4CYP2D6MAPT | |
| SCHEMBL31135220 | 0.81 | SLC5A2 (0.41) | SLC5A2CYP2C19CYP3A4CYP2D6MAPT | |
| SCHEMBL4633309 | 0.81 | SLC5A2 (0.53) | SLC5A2CYP2C19CYP3A4CYP2D6MAPT | |
| SCHEMBL3204458 | 0.81 | SLC6A2 (0.42) | SLC6A2SLC6A4SLC6A3CYP2C19CYP3A4 | |
| SCHEMBL7155412 | 0.81 | SLC5A2 (0.53) | SLC5A2CYP2C19CYP3A4CYP2D6MAPT | |
| SCHEMBL7154382 | 0.81 | SLC5A2 (0.41) | SLC5A2CYP2C19CYP3A4CYP2D6MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1549651-B1 | PYRIMIDOPYRIMIDONES AS KINASE INHIBITORS | WARNER LAMBERT CO (US) | 2009-12-23 | — | — | EP | disclosed |
| US-7196090-B2 | Kinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2007-03-27 | — | — | US | disclosed |
| WO-2006038112-A1 | USE OF KINASE INHIBITORS TO PROMOTE NEOCHONDROGENESIS | WARNER-LAMBERT COMPANY LLC (US) | 2006-04-13 | — | — | WO | disclosed |
| EP-1549651-A1 | KINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004011465-A1 | KINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-05 | — | — | WO | disclosed |
| US-20040019210-A1 | Kinase inhibitors | CHIVIKAS CONNOLLY CLEO J (US) | 2004-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019210-A1 | Kinase inhibitors | CDK2, CDK1, CDK4 | SLC5A2 3660/4885SLC6A2 4680/4885SLC6A4 4773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.